Schleich H G, Wiest W, Schmidt R, Hofmann I, Altenburg H P, Melchert F
Frauenklinik des Klinikums der Stadt Mannheim, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg, Federal Republic of Germany.
J Cancer Res Clin Oncol. 1987;113(6):603-7. doi: 10.1007/BF00390874.
Ovarian carcinomas are distinguished by their polyclonality, i.e., heterogeneity and polymorphism of their tissue. There is no marker available complying with the clinical demands in the case of ovarian carcinoma regarding satisfactory sensitivity and specificity. Therefore, we have simultaneously determined two entirely distinct tumor markers, serum ribonuclease activity (SRA) and cancer antigen 125 (CA 125), recommended in the literature with respect to ovarian carcinoma. After evaluation by logistic regression analysis, we found a specificity of 93% together with a sensitivity of 97% for the simultaneous determination of SRA and CA 125 (37 ovarian carcinomas, 11 cases without pathological findings after treatment, 11 benign tumors of the ovary, 61 controls). The patients are not exposed to increased stress by this simultaneous determination method compared to the determination of a single marker. The increased clinical validity justifies the recommendation of routine simultaneous determinations of SRA and CA 125 for diagnosis and monitoring of patients with ovarian carcinoma.
卵巢癌的特征在于其多克隆性，即其组织的异质性和多态性。在卵巢癌病例中，没有一种标志物能满足临床对令人满意的敏感性和特异性的要求。因此，我们同时测定了两种完全不同的肿瘤标志物，即血清核糖核酸酶活性（SRA）和癌抗原125（CA 125），这两种标志物在文献中被推荐用于卵巢癌。经逻辑回归分析评估，我们发现同时测定SRA和CA 125时（37例卵巢癌、11例治疗后无病理结果的病例、11例卵巢良性肿瘤、61例对照），特异性为93%，敏感性为97%。与测定单一标志物相比，这种同时测定方法不会给患者带来更大的压力。临床有效性的提高证明了推荐对卵巢癌患者进行SRA和CA 125常规同时测定以用于诊断和监测的合理性。
